Optimization of a WGA-Free Molecular Tagging-Based NGS Protocol for CTCs Mutational Profiling
Open Access
- 19 June 2020
- journal article
- research article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 21 (12), 4364
- https://doi.org/10.3390/ijms21124364
Abstract
Molecular characterization of Circulating Tumor Cells (CTCs) is still challenging, despite attempts to minimize the drawbacks of Whole Genome Amplification (WGA). In this paper, we propose a Next-Generation Sequencing (NGS) optimized protocol based on molecular tagging technology, in order to detect CTCs mutations while skipping the WGA step. MDA-MB-231 and MCF-7 cell lines, as well as leukocytes, were sorted into pools (2–5 cells) using a DEPArray™ system and were employed to set up the overall NGS procedure. A substantial reduction of reagent volume for the preparation of libraries was performed, in order to fit the limited DNA templates directly derived from cell lysates. Known variants in TP53, KRAS, and PIK3CA genes were detected in almost all the cell line pools (35/37 pools, 94.6%). No additional alterations, other than those which were expected, were found in all tested pools and no mutations were detected in leukocytes. The translational value of the optimized NGS workflow is confirmed by sequencing CTCs pools isolated from eight breast cancer patients and through the successful detection of variants. In conclusion, this study shows that the proposed NGS molecular tagging approach is technically feasible and, compared to traditional NGS approaches, has the advantage of filtering out the artifacts generated during library amplification, allowing for the reliable detection of mutations and, thus, making it highly promising for clinical use.Funding Information
- Associazione Italiana per la Ricerca sul Cancro (20760)
- Ministero della Salute (5x1000, funds 2015-2016)
This publication has 44 references indexed in Scilit:
- Association of Circulating Tumor Cells With Late Recurrence of Estrogen Receptor–Positive Breast CancerJAMA Oncology, 2018
- Liquid biopsiesGenes, Chromosomes and Cancer, 2018
- Clinical indications for, and the future of, circulating tumor cellsAdvanced Drug Delivery Reviews, 2018
- Clinical Applications of Circulating Tumor Cells and Circulating Tumor DNA as Liquid BiopsyCancer Discovery, 2016
- Meta-analysis of the prognostic value of circulating tumor cells detected with the CellSearch System in colorectal cancerBMC Cancer, 2015
- Clinical validity of circulating tumour cells in patients with metastatic breast cancer: a pooled analysis of individual patient dataThe Lancet Oncology, 2014
- Circulating Tumor Cells: Liquid Biopsy of CancerClinical Chemistry, 2013
- Evaluation and Prognostic Significance of Circulating Tumor Cells in Patients With Non–Small-Cell Lung CancerJournal of Clinical Oncology, 2011
- Circulating tumor cells: approaches to isolation and characterizationThe Journal of cell biology, 2011
- Circulating tumour cells early predict progression-free and overall survival in advanced colorectal cancer patients treated with chemotherapy and targeted agentsAnnals of Oncology, 2009